Navigation Links
Heptares to Moderate Panel on Rare Diseases at BBC New York CEO Meeting (13-14 February)
Date:2/8/2013

WELWYN GARDEN CITY, England and BOSTON, February 8, 2013 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery company, announces that its President, Dan Grau , will attend the Boston Biotech Conference New York CEO Meeting taking place on 13-14 February at Apella in New York City, NY, USA, at which he will moderate a panel on Rare Diseases (3:30pm EST, 14 February).

For a full list of events at which Heptares will be present, please visit http://www.heptares.com

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, AstraZeneca, MedImmune, Takeda and Cubist, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com.


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
2. Heptares Solves First Family B GPCR Structure
3. Heptares to Present at BIO-Europe 2012
4. Ali Velshi To Moderate The Food Dialogues (SM): New York On Nov. 15
5. Lucintel Estimates Moderate Growth for Global Pulp and Paper Chemical Industry during 2012-2017
6. Urologists Outraged over Government Panels Recommendation to Stop Life-Saving Prostate Cancer Testing
7. OBN Adds World Class Pharma and VC Figures to its Thematic Advisory Panels
8. NSF awards $450,000 to UNH, Conductive Compounds Inc. for solar panel innovation
9. WaferGens MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
10. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
11. Researchers Identify New Regulator in Allergic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight is ... HIV infection and the number of deaths due to AIDS ... across the globe. It has been estimated that the death ... 2013, with the rates for children being even much lower. ... rates has been the improved access to antiretroviral drugs and ...
(Date:8/18/2014)... , Aug. 18, 2014 TNI BioTech, Inc. ... pioneering the manufacturing and marketing of innovative therapies for ... Company is providing a second notice of TNI BioTech,s ... making the announcement, Noreen Griffin , founder and ... advance for your participation in the Annual Meeting. On ...
(Date:8/18/2014)... August 2014 Vier führende deutsche ... klinische Studie auf, in der eine Intraokularlinse ... das Sehvermögen bei allen Entfernungen verbessern, so ... keine Lese- oder Gleitsichtbrille mehr benötigen. Die ... FluidVision Accommodating Intraocular Lens (FluidVision akkomodative ...
(Date:8/16/2014)... a way to make atomic-force microscope probes 20 times ... as the weight of an individual virus. , The ... (ANU), hinges on using laser beams to cool a ... level of sensitivity achieved after cooling is accurate enough ... virus that is 100 billion times lighter than a ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4Laser makes microscopes way cooler 2
... , ... ... ... ...
... , ... ... ... ...
... ... ... ... ...
Cached Biology Technology:PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 2PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 3PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 4PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 5PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 6PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 7PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 8PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 9PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 10PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 11PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 12PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 13PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 14PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 15PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 16AMA Honors NIH Chief Molecular Biologist Ira Pastan, M.D. With Top Government Service Award 2AMA Honors NIH Chief Molecular Biologist Ira Pastan, M.D. With Top Government Service Award 3YM sees nimotuzumab license unaffected by civil claim against licensor 2YM sees nimotuzumab license unaffected by civil claim against licensor 3YM sees nimotuzumab license unaffected by civil claim against licensor 4YM sees nimotuzumab license unaffected by civil claim against licensor 5
(Date:8/19/2014)... Some infants born with neonatal abstinence syndrome (NAS) ... difficult time going through withdrawal than others, but ... genetic and epigenetic (when genes are turned on ... potential factors, researchers at Boston University School of ... a first of its kind study to identify ...
(Date:8/19/2014)... in college biology and other science courses are ... ways, and now they have a new textbook ... Life Sciences," published this month by Princeton Press ... for Mathematical and Biological Synthesis (NIMBioS), teaches readers ... be used to explore and explain biological phenomena. ...
(Date:8/19/2014)... been awarded a nearly $40,000 grant from the National ... of the National Park Service (NPS) and U.S. Department ... study of the energy efficiency and cost effectiveness of ... climates. , Radiant barriers are reflective thermal insulations commonly ... thereby reducing the amount of heat emitted in the ...
Breaking Biology News(10 mins):In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2New textbook introduces undergraduates to mathematics for the life sciences 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... Va.Catheter Lysis of Thromboembolic Stroke (CLOTS)an intensive five-day ... Oct. 24-28 in Dallas, Texasprovides interventional radiologists, neurointerventionalists, ... opportunity to review, observe and discuss all aspects ... the third-leading cause of death in the United ...
... 2010 A yearlong beach study led by a ... at sub-tropical beaches face an increased risk of illness. ... beachgoers face when exposed to recreational marine water at ... contamination. B.E.A.C.H.E.S. (Beach Environmental Assessment and ...
... Calif. , July 28 DigitalPersona, ... protection solutions, today announced DigitalPersona® Pro Enterprise, a ... protection and communication security.  DigitalPersona Pro Enterprise helps ... mobile workforces -- full disk encryption (FDE), two-factor ...
Cached Biology News:Explore stroke care with Society of Interventional Radiology's CLOTS 2Study suggests swimmers at sub-tropical beaches show increased risk of illness 2DigitalPersona Delivers New Centrally-Managed Solution for Notebook Data Protection and Remote Access Security 2DigitalPersona Delivers New Centrally-Managed Solution for Notebook Data Protection and Remote Access Security 3DigitalPersona Delivers New Centrally-Managed Solution for Notebook Data Protection and Remote Access Security 4
... The DNA Engine Tetrad thermal cycler ... the pioneering PTC-200 DNA Engine cycler. ... the capacity with a footprint only ... throughput for laboratories that run massive ...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... is for 2-D separations. The cell has a ... II xi multi-cell can be customized for several ... and cooling system. The PROTEAN II xi multi-cell ... XL multi-cell for a wider format that accommodates ...
Biology Products: